Cellectis SA
(NASDAQ:CLLS)
$2.25
-0.13[-5.46%]
At close: Feb 8
$2.37
0.1200[5.33%]
After Hours: 9:30AM EDT
Day Range2.250 - 2.39052 Wk Range1.830 - 6.010Open / Close2.350 / 2.250Float / Outstanding45.130M / 55.474M
Vol / Avg.266.583K / 160.025KMkt Cap124.816MP/E-50d Avg. Price2.600
Div / Yield (Forward)- / -%Payout Ratio-Total Float45.130MEPS-2.290

Cellectis Stock (NASDAQ:CLLS), Quotes and News Summary

Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.

Loading...
Day Range2.250 - 2.39052 Wk Range1.830 - 6.010Open / Close2.350 / 2.250Float / Outstanding45.130M / 55.474M
Vol / Avg.266.583K / 160.025KMkt Cap124.816MP/E-50d Avg. Price2.600
Div / Yield (Forward)- / -%Payout Ratio-Total Float45.130MEPS-2.290
InvestorPlace - Jan 30, 2023, 7:10PM
InvestorsObserver - Jan 23, 2023, 9:32AM
InvestorPlace - Jan 17, 2023, 8:10AM
Seeking Alpha - Jan 10, 2023, 8:25AM
Seeking Alpha - Nov 29, 2022, 11:44AM
InvestorsObserver - Nov 15, 2022, 8:13AM
InvestorsObserver - Nov 10, 2022, 7:14AM
Seeking Alpha - Nov 2, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-02
REV
Q3 2022Est.ActualSurprise
EPS-0.450-0.580 -0.1300
REV13.430M1.921M-11.509M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Cellectis (CLLS) stock?

A

You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Cellectis (CLLS) stock?

A

The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Cellectis (CLLS)?

A

The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Cellectis (CLLS) pay a dividend?

A

There are no upcoming dividends for Cellectis.

Q

When is Cellectis (NASDAQ:CLLS) reporting earnings?

A

Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.

Q

Is Cellectis (CLLS) going to split?

A

There is no upcoming split for Cellectis.

Q

What sector and industry does Cellectis (CLLS) operate in?

A

Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Cellectis Stock (NASDAQ:CLLS), Quotes and News Summary

Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.

Loading...
Day Range2.250 - 2.39052 Wk Range1.830 - 6.010Open / Close2.350 / 2.250Float / Outstanding45.130M / 55.474M
Vol / Avg.266.583K / 160.025KMkt Cap124.816MP/E-50d Avg. Price2.600
Div / Yield (Forward)- / -%Payout Ratio-Total Float45.130MEPS-2.290
InvestorPlace - Jan 30, 2023, 7:10PM
InvestorsObserver - Jan 23, 2023, 9:32AM
InvestorPlace - Jan 17, 2023, 8:10AM
Seeking Alpha - Jan 10, 2023, 8:25AM
Seeking Alpha - Nov 29, 2022, 11:44AM
InvestorsObserver - Nov 15, 2022, 8:13AM
InvestorsObserver - Nov 10, 2022, 7:14AM
Seeking Alpha - Nov 2, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-02
REV
Q3 2022Est.ActualSurprise
EPS-0.450-0.580 -0.1300
REV13.430M1.921M-11.509M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Cellectis (CLLS) stock?

A

You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Cellectis (CLLS) stock?

A

The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Cellectis (CLLS)?

A

The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Cellectis (CLLS) pay a dividend?

A

There are no upcoming dividends for Cellectis.

Q

When is Cellectis (NASDAQ:CLLS) reporting earnings?

A

Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.

Q

Is Cellectis (CLLS) going to split?

A

There is no upcoming split for Cellectis.

Q

What sector and industry does Cellectis (CLLS) operate in?

A

Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Cellectis Stock (NASDAQ:CLLS), Quotes and News Summary

Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.

Loading...
Day Range2.250 - 2.39052 Wk Range1.830 - 6.010Open / Close2.350 / 2.250Float / Outstanding45.130M / 55.474M
Vol / Avg.266.583K / 160.025KMkt Cap124.816MP/E-50d Avg. Price2.600
Div / Yield (Forward)- / -%Payout Ratio-Total Float45.130MEPS-2.290
InvestorPlace - Jan 30, 2023, 7:10PM
InvestorsObserver - Jan 23, 2023, 9:32AM
InvestorPlace - Jan 17, 2023, 8:10AM
Seeking Alpha - Jan 10, 2023, 8:25AM
Seeking Alpha - Nov 29, 2022, 11:44AM
InvestorsObserver - Nov 15, 2022, 8:13AM
InvestorsObserver - Nov 10, 2022, 7:14AM
Seeking Alpha - Nov 2, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-02
REV
Q3 2022Est.ActualSurprise
EPS-0.450-0.580 -0.1300
REV13.430M1.921M-11.509M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Cellectis (CLLS) stock?

A

You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Cellectis (CLLS) stock?

A

The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Cellectis (CLLS)?

A

The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Cellectis (CLLS) pay a dividend?

A

There are no upcoming dividends for Cellectis.

Q

When is Cellectis (NASDAQ:CLLS) reporting earnings?

A

Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.

Q

Is Cellectis (CLLS) going to split?

A

There is no upcoming split for Cellectis.

Q

What sector and industry does Cellectis (CLLS) operate in?

A

Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Cellectis Stock (NASDAQ:CLLS), Quotes and News Summary

Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.

Loading...
Day Range2.250 - 2.39052 Wk Range1.830 - 6.010Open / Close2.350 / 2.250Float / Outstanding45.130M / 55.474M
Vol / Avg.266.583K / 160.025KMkt Cap124.816MP/E-50d Avg. Price2.600
Div / Yield (Forward)- / -%Payout Ratio-Total Float45.130MEPS-2.290
InvestorPlace - Jan 30, 2023, 7:10PM
InvestorsObserver - Jan 23, 2023, 9:32AM
InvestorPlace - Jan 17, 2023, 8:10AM
Seeking Alpha - Jan 10, 2023, 8:25AM
Seeking Alpha - Nov 29, 2022, 11:44AM
InvestorsObserver - Nov 15, 2022, 8:13AM
InvestorsObserver - Nov 10, 2022, 7:14AM
Seeking Alpha - Nov 2, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-02
REV
Q3 2022Est.ActualSurprise
EPS-0.450-0.580 -0.1300
REV13.430M1.921M-11.509M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Cellectis (CLLS) stock?

A

You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Cellectis (CLLS) stock?

A

The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Cellectis (CLLS)?

A

The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Cellectis (CLLS) pay a dividend?

A

There are no upcoming dividends for Cellectis.

Q

When is Cellectis (NASDAQ:CLLS) reporting earnings?

A

Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.

Q

Is Cellectis (CLLS) going to split?

A

There is no upcoming split for Cellectis.

Q

What sector and industry does Cellectis (CLLS) operate in?

A

Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Cellectis Stock (NASDAQ:CLLS), Quotes and News Summary

Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.

Loading...
Day Range2.250 - 2.39052 Wk Range1.830 - 6.010Open / Close2.350 / 2.250Float / Outstanding45.130M / 55.474M
Vol / Avg.266.583K / 160.025KMkt Cap124.816MP/E-50d Avg. Price2.600
Div / Yield (Forward)- / -%Payout Ratio-Total Float45.130MEPS-2.290
InvestorPlace - Jan 30, 2023, 7:10PM
InvestorsObserver - Jan 23, 2023, 9:32AM
InvestorPlace - Jan 17, 2023, 8:10AM
Seeking Alpha - Jan 10, 2023, 8:25AM
Seeking Alpha - Nov 29, 2022, 11:44AM
InvestorsObserver - Nov 15, 2022, 8:13AM
InvestorsObserver - Nov 10, 2022, 7:14AM
Seeking Alpha - Nov 2, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-02
REV
Q3 2022Est.ActualSurprise
EPS-0.450-0.580 -0.1300
REV13.430M1.921M-11.509M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Cellectis (CLLS) stock?

A

You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Cellectis (CLLS) stock?

A

The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Cellectis (CLLS)?

A

The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Cellectis (CLLS) pay a dividend?

A

There are no upcoming dividends for Cellectis.

Q

When is Cellectis (NASDAQ:CLLS) reporting earnings?

A

Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.

Q

Is Cellectis (CLLS) going to split?

A

There is no upcoming split for Cellectis.

Q

What sector and industry does Cellectis (CLLS) operate in?

A

Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Cellectis Stock (NASDAQ:CLLS), Quotes and News Summary

Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.

Loading...
Day Range2.250 - 2.39052 Wk Range1.830 - 6.010Open / Close2.350 / 2.250Float / Outstanding45.130M / 55.474M
Vol / Avg.266.583K / 160.025KMkt Cap124.816MP/E-50d Avg. Price2.600
Div / Yield (Forward)- / -%Payout Ratio-Total Float45.130MEPS-2.290
InvestorPlace - Jan 30, 2023, 7:10PM
InvestorsObserver - Jan 23, 2023, 9:32AM
InvestorPlace - Jan 17, 2023, 8:10AM
Seeking Alpha - Jan 10, 2023, 8:25AM
Seeking Alpha - Nov 29, 2022, 11:44AM
InvestorsObserver - Nov 15, 2022, 8:13AM
InvestorsObserver - Nov 10, 2022, 7:14AM
Seeking Alpha - Nov 2, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-02
REV
Q3 2022Est.ActualSurprise
EPS-0.450-0.580 -0.1300
REV13.430M1.921M-11.509M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Cellectis (CLLS) stock?

A

You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Cellectis (CLLS) stock?

A

The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Cellectis (CLLS)?

A

The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Cellectis (CLLS) pay a dividend?

A

There are no upcoming dividends for Cellectis.

Q

When is Cellectis (NASDAQ:CLLS) reporting earnings?

A

Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.

Q

Is Cellectis (CLLS) going to split?

A

There is no upcoming split for Cellectis.

Q

What sector and industry does Cellectis (CLLS) operate in?

A

Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Cellectis Stock (NASDAQ:CLLS), Quotes and News Summary

Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.

Loading...
Day Range2.250 - 2.39052 Wk Range1.830 - 6.010Open / Close2.350 / 2.250Float / Outstanding45.130M / 55.474M
Vol / Avg.266.583K / 160.025KMkt Cap124.816MP/E-50d Avg. Price2.600
Div / Yield (Forward)- / -%Payout Ratio-Total Float45.130MEPS-2.290
InvestorPlace - Jan 30, 2023, 7:10PM
InvestorsObserver - Jan 23, 2023, 9:32AM
InvestorPlace - Jan 17, 2023, 8:10AM
Seeking Alpha - Jan 10, 2023, 8:25AM
Seeking Alpha - Nov 29, 2022, 11:44AM
InvestorsObserver - Nov 15, 2022, 8:13AM
InvestorsObserver - Nov 10, 2022, 7:14AM
Seeking Alpha - Nov 2, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-02
REV
Q3 2022Est.ActualSurprise
EPS-0.450-0.580 -0.1300
REV13.430M1.921M-11.509M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Cellectis (CLLS) stock?

A

You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Cellectis (CLLS) stock?

A

The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Cellectis (CLLS)?

A

The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Cellectis (CLLS) pay a dividend?

A

There are no upcoming dividends for Cellectis.

Q

When is Cellectis (NASDAQ:CLLS) reporting earnings?

A

Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.

Q

Is Cellectis (CLLS) going to split?

A

There is no upcoming split for Cellectis.

Q

What sector and industry does Cellectis (CLLS) operate in?

A

Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Cellectis Stock (NASDAQ:CLLS), Quotes and News Summary

Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.

Loading...
Day Range2.250 - 2.39052 Wk Range1.830 - 6.010Open / Close2.350 / 2.250Float / Outstanding45.130M / 55.474M
Vol / Avg.266.583K / 160.025KMkt Cap124.816MP/E-50d Avg. Price2.600
Div / Yield (Forward)- / -%Payout Ratio-Total Float45.130MEPS-2.290
InvestorPlace - Jan 30, 2023, 7:10PM
InvestorsObserver - Jan 23, 2023, 9:32AM
InvestorPlace - Jan 17, 2023, 8:10AM
Seeking Alpha - Jan 10, 2023, 8:25AM
Seeking Alpha - Nov 29, 2022, 11:44AM
InvestorsObserver - Nov 15, 2022, 8:13AM
InvestorsObserver - Nov 10, 2022, 7:14AM
Seeking Alpha - Nov 2, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-02
REV
Q3 2022Est.ActualSurprise
EPS-0.450-0.580 -0.1300
REV13.430M1.921M-11.509M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Cellectis (CLLS) stock?

A

You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Cellectis (CLLS) stock?

A

The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Cellectis (CLLS)?

A

The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Cellectis (CLLS) pay a dividend?

A

There are no upcoming dividends for Cellectis.

Q

When is Cellectis (NASDAQ:CLLS) reporting earnings?

A

Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.

Q

Is Cellectis (CLLS) going to split?

A

There is no upcoming split for Cellectis.

Q

What sector and industry does Cellectis (CLLS) operate in?

A

Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Cellectis Stock (NASDAQ:CLLS), Quotes and News Summary

Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.

Loading...
Day Range2.250 - 2.39052 Wk Range1.830 - 6.010Open / Close2.350 / 2.250Float / Outstanding45.130M / 55.474M
Vol / Avg.266.583K / 160.025KMkt Cap124.816MP/E-50d Avg. Price2.600
Div / Yield (Forward)- / -%Payout Ratio-Total Float45.130MEPS-2.290
InvestorPlace - Jan 30, 2023, 7:10PM
InvestorsObserver - Jan 23, 2023, 9:32AM
InvestorPlace - Jan 17, 2023, 8:10AM
Seeking Alpha - Jan 10, 2023, 8:25AM
Seeking Alpha - Nov 29, 2022, 11:44AM
InvestorsObserver - Nov 15, 2022, 8:13AM
InvestorsObserver - Nov 10, 2022, 7:14AM
Seeking Alpha - Nov 2, 2022, 5:35PM
Sector: Health Care.Industry: Biotechnology
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-02
REV
Q3 2022Est.ActualSurprise
EPS-0.450-0.580 -0.1300
REV13.430M1.921M-11.509M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Cellectis (CLLS) stock?

A

You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.

View our list of the best stock brokerages.

Q

What is the target price for Cellectis (CLLS) stock?

A

The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Cellectis (CLLS)?

A

The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.

Q

Does Cellectis (CLLS) pay a dividend?

A

There are no upcoming dividends for Cellectis.

Q

When is Cellectis (NASDAQ:CLLS) reporting earnings?

A

Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.

Q

Is Cellectis (CLLS) going to split?

A

There is no upcoming split for Cellectis.

Q

What sector and industry does Cellectis (CLLS) operate in?

A

Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.